RED1,2,3: NICE TA34: trastuzumab in combination with paclitaxel is recommended for women with tumours with excessive human epidermal growth factor receptor 2 (HER2) at levels of 3+ who have not had chemotherapy for metastatic breast cancer and for whom anthracycline treatment is inappropriate. (March 2002)
RED1,2,3:NICE TA107: Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence (whichever is the shorter period), is recommended as a treatment option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).(August 2006)
RED1,2,3:NICE TA208: Trastuzumab, in combination with cisplatin and capecitabine or 5-fluorouracil, is recommended as an option for the treatment of people with HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. (Nov 2010)
DO NOT PRESCRIBE (DNP)6:NICE TA257: Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) are not recommended for first-line treatment in post-menopausal women with metastatic hormone receptor positive breast cancer that overexpresses HER2. (Decision date - July 2012)
